RT Journal Article
SR Electronic
T1 Metabolism of 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2 in humans.
JF Drug Metabolism and Disposition
JO Drug Metab Dispos
FD American Society for Pharmacology and Experimental Therapeutics
SP 255
OP 265
VO 11
IS 3
A1 S Steffenrud
YR 1983
UL http://dmd.aspetjournals.org/content/11/3/255.abstract
AB Tritium-labeled 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2 was administered by intravenous injection into humans. The initial half-life in plasma was determined to be about 3 min. About 35% of the injected radioactivity was excreted in the urine and about 55% in the feces. Twenty-three urinary metabolites were identified. The metabolites included beta-oxidized and omega-oxidized products as well as metabolites in which the 9-methylene group had been biotransformed.